Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
about
Teriflunomide for multiple sclerosisTeriflunomide for multiple sclerosisTeriflunomide for multiple sclerosisLeflunomide: mode of action in the treatment of rheumatoid arthritisImpact of Exercise on Innate Immunity in Multiple Sclerosis Progression and SymptomatologyRegulation of STATs by polycystin-1 and their role in polycystic kidney diseaseBenefits versus risks of latest therapies in multiple sclerosis: a perspective reviewDevelopment of oral immunomodulatory agents in the management of multiple sclerosisLeflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivoChallenges and treatment options for rheumatoid arthritis during pregnancy.High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism.Babesia bovis dihydroorotate dehydrogenase (BboDHODH) is a novel molecular target of drug for bovine babesiosisPlasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway.An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.Risk stratification and mitigation multiple sclerosis.Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis.The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells.Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis.The role of the de novo pyrimidine biosynthetic pathway in Cryptococcus neoformans high temperature growth and virulence.The importance of mitochondrial DNA in aging and cancer.Oral disease-modifying therapies for multiple sclerosis.Leflunomide for the treatment of rheumatoid arthritis.Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease.Leflunomide: long-term clinical experience and new uses.Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients.Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication.Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomideReview of teriflunomide and its potential in the treatment of multiple sclerosis.Drugs in development for relapsing multiple sclerosis.Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.Proposal for a new nomenclature of disease-modifying antirheumatic drugs.Teriflunomide: a review of its use in relapsing multiple sclerosis.Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosisSafety of teriflunomide for the management of relapsing-remitting multiple sclerosis.Regulation of human glia by multiple sclerosis disease modifying therapies.Dendritic cells as therapeutic targets in neuroinflammation.Teriflunomide for oral therapy in multiple sclerosis.Effects of long-term oral treatment with leflunomide on allergic sensitization, lymphocyte activation, and airway inflammation in a rat model of asthma.
P2860
Q24186016-57B5C349-CBEB-4A00-8A37-891BC75F6211Q24198146-3A7BB8A8-C4E0-418E-A318-65E4533FD363Q24202177-BCD7F51A-C491-4FA2-A0ED-AD9F55644CDDQ24675005-8F4BD0EF-1EBF-464F-B20C-EE6F6455E7BBQ26745562-3E09CB4B-DB16-44EA-A4E7-27A2FDCAF487Q26852136-F2D98639-5B43-4BB2-896B-1BD70405305CQ26999417-429C83B2-5F57-40BA-B663-818ABCBFF702Q28388704-6197C06B-6589-4A24-980E-A0269527CC6EQ28535313-41EEB1F3-AA5F-4E39-8539-0EC523E734E2Q30249730-C4BB5094-5325-40C1-9E1B-A3CDD1DE9159Q31156888-5B11548C-2D36-4612-9637-7DCB5B7A04EBQ33380457-24CE8B54-0E89-477C-97BB-D687634AD551Q33579509-738D7F75-A1EB-48A5-8345-DDC013020446Q33903812-2F3EF604-8005-4FF4-9396-C44E1ADBB7FDQ34059286-C6C6EEC4-181F-451E-B25E-E56376798575Q34066654-A7F38E68-88D7-4B37-9771-75E9EFE2CF70Q34155446-BAAEC1F2-5C24-46DF-942D-1A8AD4DB2DEBQ34240771-BCB834C7-04CC-451F-836C-6D458648ECEEQ34345424-A4DDA7E4-B8D5-41A2-A4D4-16EE7E395114Q34805086-BA88B1A7-42C2-4BAF-93DF-05003C6443BDQ34856009-52CFF3FF-334C-4B42-AB50-3F2DE0E8A099Q34974582-C1809A3D-4F58-4D36-885F-56C23D5F6CDFQ34996562-0C4FCC1A-D114-451E-9268-BEB946A365CFQ35143977-4D3808D5-1A5F-4AFF-A0BB-458E41EAE4B6Q35518697-B76F8C61-42C7-4D1B-B583-2B8E1C5FCA5AQ36150789-9489DD0D-A6E2-4D4B-B405-CA6776F8C883Q36662024-05314FD5-42EA-402F-B3C9-184E6ACDA4E4Q36887749-0AA98F92-441A-49C8-90EE-F1E194825E0FQ36899427-BEE75CBC-C1CD-44D4-8EE9-4BF4A59422B9Q37235715-74691785-02F6-45F3-8A10-2B3BD22372EEQ38101004-F526402F-9788-4DED-B5E6-5DCEB2E5667FQ38107524-CC01F311-996D-4A96-9089-7F61E2E445B9Q38144973-69ACFB44-40F0-4FD2-835E-98EBC68E2CF1Q38160410-3AA0F20A-DE70-4417-9C23-13DFC5518439Q38216015-D6FEB23F-6319-42C6-873E-49FB6B96527FQ38357590-F19EDA4B-5ED0-43EF-A3FC-72CA173B448DQ38563863-15745411-C2AB-4312-9EF8-6979DB9A5C41Q38771884-AFBFF714-6CEF-4231-BA62-0063B5416C82Q39504360-8A6F3E4D-E759-4CFA-B57C-B3D3D71C5EF4Q40849939-CFEEC401-89A8-4C76-9304-685612EFAE97
P2860
Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
@en
type
label
Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
@en
prefLabel
Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
@en
P2093
P1476
Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
@en
P2093
Braatz-Trulson J
Watanabe K
P304
P356
10.1016/0006-2952(95)00255-X
P407
P577
1995-09-01T00:00:00Z